Demographic and clinical characteristics associated with variations in antibody response to BNT162b2 COVID-19 vaccination among healthcare workers at an academic medical centre: a longitudinal cohort analysis.
COVID-19
hypertension
infectious diseases
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
24 05 2022
24 05 2022
Historique:
entrez:
25
5
2022
pubmed:
26
5
2022
medline:
28
5
2022
Statut:
epublish
Résumé
We sought to understand the demographic and clinical factors associated with variations in longitudinal antibody response following completion of two-dose regiment of BNT162b2 vaccination. This study is a 10-month longitudinal cohort study of healthcare workers and serially measured anti-spike protein IgG (IgG-S) antibody levels using mixed linear models to examine their associations with participant characteristics. A large, multisite academic medical centre in Southern California, USA. A total of 843 healthcare workers met inclusion criteria including completion of an initial two-dose course of BNT162b2 vaccination, complete clinical history and at least two blood samples for analysis. Patients had an average age of 45±13 years, were 70% female and 7% with prior SARS-CoV-2 infection. Vaccine-induced IgG-S levels remained in the positive range for 99.6% of individuals up to 10 months after initial two-dose vaccination. Prior SARS-CoV-2 infection was the primary correlate of sustained higher postvaccination IgG-S levels (partial R While the IgG-S antibody response remains in the positive range for up to 10 months following initial mRNA vaccination in most adults, determinants of sustained higher antibody levels include prior SARS-CoV-2 infection, female sex, younger age and absence of hypertension. Certain determinants of the longitudinal antibody response appear significantly modified by prior infection status. These findings offer insights regarding factors that may influence the 'hybrid' immunity conferred by natural infection combined with vaccination.
Identifiants
pubmed: 35613792
pii: bmjopen-2021-059994
doi: 10.1136/bmjopen-2021-059994
pmc: PMC9130668
doi:
Substances chimiques
Antibodies, Viral
0
COVID-19 Vaccines
0
Immunoglobulin G
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e059994Subventions
Organisme : NHLBI NIH HHS
ID : K23 HL153888
Pays : United States
Organisme : NIA NIH HHS
ID : U54 AG065141
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL137076
Pays : United States
Organisme : NIDDK NIH HHS
ID : P01 DK046763
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL155759
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL159953
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL111362
Pays : United States
Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: JCP, ECF and JLS work for Abbott Diagnostics, a company that performed the serological assays on the biospecimens that were collected for this study.
Références
Nature. 2021 Aug;596(7872):417-422
pubmed: 34192737
Emerg Infect Dis. 2020 Sep;26(9):1978-1986
pubmed: 32544053
Lancet. 2021 Jul 31;398(10298):385-387
pubmed: 34274038
Immunol Res. 2014 Aug;59(1-3):243-53
pubmed: 24847766
BMJ Open. 2021 Feb 12;11(2):e043584
pubmed: 33579769
Vaccine. 2021 Oct 22;39(44):6492-6509
pubmed: 34600747
J Infect Dis. 2021 Sep 1;224(5):793-797
pubmed: 34117873
Annu Rev Cell Dev Biol. 2017 Oct 6;33:577-599
pubmed: 28992436
Epidemiol Infect. 2020 Dec 02;148:e299
pubmed: 33261680
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
JAMA Netw Open. 2021 Sep 1;4(9):e2124331
pubmed: 34473262
N Engl J Med. 2021 Oct 14;385(16):1474-1484
pubmed: 34320281
Nature. 2021 Dec;600(7889):517-522
pubmed: 34619745
Clin Immunol. 2020 Mar;212:108247
pubmed: 31401215
JAMA. 2021 Dec 28;326(24):2524-2526
pubmed: 34724529
Cell Rep Med. 2021 Jul 20;2(7):100354
pubmed: 34250512
Nat Med. 2021 Jun;27(6):981-984
pubmed: 33795870
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
Sci Immunol. 2020 Dec 7;5(54):
pubmed: 33288645
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Cell Host Microbe. 2021 Apr 14;29(4):516-521.e3
pubmed: 33798491
N Engl J Med. 2021 Oct 7;385(15):1393-1400
pubmed: 34525275
Science. 2021 Sep 17;373(6561):eabj0299
pubmed: 34529476
Science. 2021 Mar 25;:
pubmed: 33766944
Nature. 2021 Jul;595(7867):426-431
pubmed: 34126625
Am J Epidemiol. 2018 Jan 1;187(1):135-143
pubmed: 29309522
Lancet Respir Med. 2021 Sep;9(9):999-1009
pubmed: 34224675